Showing 2661-2670 of 3223 results for "".
- LumiThera Acquires Diopsys, Provider of Light-Based Theranostic Approach to Treat Ocular Diseasehttps://modernod.com/news/lumithera-acquires-diopsys-provider-of-light-based-theranostic-approach-to-treat-ocular-disease/2480430/LumiThera announced its entry into a definitive merger agreement with Diopsys, a provider of modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Under the terms of
- Novartis to Sell Roche Stake for $20.7 Billionhttps://modernod.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/Novartis said Thursday that it agreed to sell its stake in Roche for $20.7 billion, with the proceeds to be used "in line with capital allocation priorities to enhance strong returns to shareholders," according to a FirstWord repor
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder
- Registration Now Open for International Sports Vision Association 6th Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/Registration is now open for Elevating Athletic Performance<
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- TissueTech Grows Salesforce to Support Footprint Expansionhttps://modernod.com/news/tissuetech-grows-salesforce-to-support-footprint-expansion/2480345/TissueTech, which applies cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds,
- AAO Updates Registration and Vaccination Requirement for Annual Meetinghttps://modernod.com/news/aao-updates-registration-and-vaccination-requirement-for-annual-meeting/2480306/The American Academy of Ophthalmology (AAO) announced that all in-person attendees of the AAO annual meeting in New Orleans will have to show proof of vaccination to enter the convention center using the Clear Health Pass app. A
- Patricia Bath, MD, Inducted Into National Inventors Hall of Famehttps://modernod.com/news/patricia-bath-md-inducted-into-national-inventors-hall-of-fame/2480295/Patricia Bath, MD, was among seven innovation pioneers inducted into the National Inventors Hall of Fame (NIHF) Dr. Bath, who was inducted posthumously, contributed to the invention of laserphaco, allowing surgeons to use ultrasound to perform all steps of cataract r
- ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lillyhttps://modernod.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/ProQR Therapeutics, the developer of RNA therapies for the treatment of genetic eye diseases, announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in